The reporter Pan Feng was organized by the National Comprehensive Cancer Network (NCCN) and supported by the Sanofi-Aventis Group. The Fourth NCCN Asian Conference was held in Shanghai on April 8. The members of NCCN experts from China and other Asian countries gathered with thousands of clinicians to carry out an informative academic exchange on the theme of “Promoting Best Evidence-Based Oncology Practiceâ€. This meeting was an updated version of NCCN Tumor in 2011. The direction of revision of the Clinical Practice Guide (China Version) is indicated.
The treatment of liver cancer is still a problem. Data from World Cancer Day 2011 show that China, as the most severely affected area of ​​liver cancer, accounts for 55% of the world's total, and the death toll accounts for 45% of the world's total. According to the 2010 China Health Statistics Yearbook, liver cancer has surpassed that of gastric cancer and ranks first in the mortality rate of gastrointestinal cancer in China. Professor Ye Shenglong, Department of Liver Cancer, Zhongshan Hospital, Fudan University, said: "Because of the high degree of malignancy, rapid progression, recurrence and metastasis of liver cancer, treatment of liver cancer is a very hard nut to doctors. Known as the "King of cancer." At present, the survival of most patients with liver cancer after diagnosis does not exceed six months."
The experts believe that although the treatment of liver cancer involves many subjects, surgical resection is still the preferred method for the treatment of liver cancer. However, the recurrence rate of up to 70% after 5 years severely restricts the efficacy of surgery. On the other hand, the early symptoms of liver cancer are not obvious, resulting in the majority of patients in the advanced stage of cancer at the time of diagnosis, and missed the ideal stage of surgical treatment.
The current treatment of liver cancer depends on the stage of the disease, residual liver function, and the patient's physical condition. However, many liver cancer patients in China have missed the best opportunity for surgical treatment when they are diagnosed, and the cost of expensive targeted drug treatment makes them unable to afford it. Therefore, how to achieve the ideal standardized comprehensive diagnosis and treatment effect through multi-disciplinary joint research has become a difficult problem to be overcome by the medical community.
A comprehensive introduction of the latest treatment guidelines During the conference, an on-going education platform for professional oncologists, the China Cancer Society oncology, was formally announced. The college is sponsored by the Chinese Anticancer Association and Sanofi-Aventis funded it exclusively. Prof. Sun Yan, academician of the Chinese Academy of Engineering, said: “The special nature of the doctor’s profession determines the importance of continuing education. If a worker wants to do something good, he must first sharpen his tools. Continuing Education Institute and Oncology Tool Network have provided doctors with very important Learning and communication platform."
At the same time, the China Anti-Cancer Association also launched the nation's first oncology tool website (.com.cn) for professional doctors, which facilitates daily learning and work communication for oncologists.
At present, the exploration of a highly effective and low-toxic system chemotherapy regimen is an urgent task for solving the Chinese-style liver cancer problem. Chairman of the Chinese Society of Clinical Oncology (CSCO), Associate Dean of the People's Liberation Army Bayi Hospital and Director of the All Army Oncology Center, Professor Qin Shujun, introduced: “An open, multi-center, randomized, controlled study conducted by CSCO and the multi-centers in the Asia Pacific region. The phase clinical study confirmed for the first time that the new FOLFOX chemotherapy regimen with oxaliplatin (leoxadine) has improved the objective remission rate of patients with advanced hepatocellular carcinoma, and the adverse reactions are also tolerable to patients and this will make people completely surrender liver cancer in the future. The beneficial exploration has opened up new prospects for the application of chemotherapy to the oncology community in China, the Asia-Pacific region, and other parts of the world.†The 2009 version of the “CSCO Expert Consensus on the Standardization of Primary Hepatocellular Carcinoma†also pointed out that in recent years Oxali has been used. The new generation of cytotoxic drugs represented by platinum have come out one after another, making the chemotherapy of gastrointestinal cancer has made great progress, the prognosis has improved significantly, and it has also promoted the research on systemic chemotherapy of liver cancer.
Professor Fan Jia, deputy dean of the Zhongshan Hospital of Fudan University and director of hepatic surgery, analyzed that: “Improving the public's awareness of liver cancer and promoting the concept of standardized life are crucial to changing the status of liver cancer in China.†For this reason, the Chinese Cancer Society The first public version of the "Guideline for Standardized Methods for Digestive Tract Cancer" was uploaded to the Internet. The public can log on to the website of the Colorectal Cancer Professional Committee of the Chinese Cancer Society. Org. Cn Read online or download it for free and share health advice from the Chinese Cancer Society. Experts agreed that in order to win a long-lasting fight against cancer, it is necessary not only to actively explore the latest medical tools in professional fields, to promote scientific and effective treatment models, but also to comprehensively improve the public's normative awareness in order to achieve an ideal therapeutic effect.
The treatment of liver cancer is still a problem. Data from World Cancer Day 2011 show that China, as the most severely affected area of ​​liver cancer, accounts for 55% of the world's total, and the death toll accounts for 45% of the world's total. According to the 2010 China Health Statistics Yearbook, liver cancer has surpassed that of gastric cancer and ranks first in the mortality rate of gastrointestinal cancer in China. Professor Ye Shenglong, Department of Liver Cancer, Zhongshan Hospital, Fudan University, said: "Because of the high degree of malignancy, rapid progression, recurrence and metastasis of liver cancer, treatment of liver cancer is a very hard nut to doctors. Known as the "King of cancer." At present, the survival of most patients with liver cancer after diagnosis does not exceed six months."
The experts believe that although the treatment of liver cancer involves many subjects, surgical resection is still the preferred method for the treatment of liver cancer. However, the recurrence rate of up to 70% after 5 years severely restricts the efficacy of surgery. On the other hand, the early symptoms of liver cancer are not obvious, resulting in the majority of patients in the advanced stage of cancer at the time of diagnosis, and missed the ideal stage of surgical treatment.
The current treatment of liver cancer depends on the stage of the disease, residual liver function, and the patient's physical condition. However, many liver cancer patients in China have missed the best opportunity for surgical treatment when they are diagnosed, and the cost of expensive targeted drug treatment makes them unable to afford it. Therefore, how to achieve the ideal standardized comprehensive diagnosis and treatment effect through multi-disciplinary joint research has become a difficult problem to be overcome by the medical community.
A comprehensive introduction of the latest treatment guidelines During the conference, an on-going education platform for professional oncologists, the China Cancer Society oncology, was formally announced. The college is sponsored by the Chinese Anticancer Association and Sanofi-Aventis funded it exclusively. Prof. Sun Yan, academician of the Chinese Academy of Engineering, said: “The special nature of the doctor’s profession determines the importance of continuing education. If a worker wants to do something good, he must first sharpen his tools. Continuing Education Institute and Oncology Tool Network have provided doctors with very important Learning and communication platform."
At the same time, the China Anti-Cancer Association also launched the nation's first oncology tool website (.com.cn) for professional doctors, which facilitates daily learning and work communication for oncologists.
At present, the exploration of a highly effective and low-toxic system chemotherapy regimen is an urgent task for solving the Chinese-style liver cancer problem. Chairman of the Chinese Society of Clinical Oncology (CSCO), Associate Dean of the People's Liberation Army Bayi Hospital and Director of the All Army Oncology Center, Professor Qin Shujun, introduced: “An open, multi-center, randomized, controlled study conducted by CSCO and the multi-centers in the Asia Pacific region. The phase clinical study confirmed for the first time that the new FOLFOX chemotherapy regimen with oxaliplatin (leoxadine) has improved the objective remission rate of patients with advanced hepatocellular carcinoma, and the adverse reactions are also tolerable to patients and this will make people completely surrender liver cancer in the future. The beneficial exploration has opened up new prospects for the application of chemotherapy to the oncology community in China, the Asia-Pacific region, and other parts of the world.†The 2009 version of the “CSCO Expert Consensus on the Standardization of Primary Hepatocellular Carcinoma†also pointed out that in recent years Oxali has been used. The new generation of cytotoxic drugs represented by platinum have come out one after another, making the chemotherapy of gastrointestinal cancer has made great progress, the prognosis has improved significantly, and it has also promoted the research on systemic chemotherapy of liver cancer.
Professor Fan Jia, deputy dean of the Zhongshan Hospital of Fudan University and director of hepatic surgery, analyzed that: “Improving the public's awareness of liver cancer and promoting the concept of standardized life are crucial to changing the status of liver cancer in China.†For this reason, the Chinese Cancer Society The first public version of the "Guideline for Standardized Methods for Digestive Tract Cancer" was uploaded to the Internet. The public can log on to the website of the Colorectal Cancer Professional Committee of the Chinese Cancer Society. Org. Cn Read online or download it for free and share health advice from the Chinese Cancer Society. Experts agreed that in order to win a long-lasting fight against cancer, it is necessary not only to actively explore the latest medical tools in professional fields, to promote scientific and effective treatment models, but also to comprehensively improve the public's normative awareness in order to achieve an ideal therapeutic effect.
China leading manufacturers and suppliers of Medical Adhesive Tape,Medical Hypoallergenic Tape, and we are specialize in Medical Breathable Tape , Medical Tape , etc.
Medical Adhesive Tape,Medical Hypoallergenic Tape,Medical Breathable Tape ,Medical Tape
Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com